Pulmovant

Executive Summary

Pulmovant, a biopharmaceutical company within the Roivant Sciences family, is dedicated to developing inhaled therapies for pulmonary diseases. Its lead candidate, mosliciguat, is an inhaled soluble guanylate cyclase (sGC) activator targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD). Founded in 2023 and based in San Diego, the company leverages a collaborative model to accelerate development. PH-ILD is a serious condition with limited treatment options, representing a significant unmet need. Mosliciguat's inhaled delivery aims to maximize local lung exposure while minimizing systemic side effects, potentially offering a differentiated profile over oral sGC stimulators. Pulmovant is currently advancing mosliciguat through preclinical and early clinical stages, with potential for further development milestones in the near term. The company's focus on a validated mechanism and its connection to Roivant Sciences provide strategic advantages, though clinical data remain limited. As a private company, Pulmovant's progress will be closely watched for proof-of-concept data and strategic partnerships.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1/2 clinical trial for mosliciguat in PH-ILD60% success
• Q3 2026Presentation of preclinical data at a major medical conference80% success
• TBDAnnouncement of strategic partnership or licensing deal for mosliciguat30% success